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ABSTRACT
The emerging zoonotic pathogens Hendra virus (HeV) and Nipah virus (NiV) are in the genusHenipavirus in the family
Paramyxoviridae. HeV and NiV infections can be highly fatal to humans and livestock. The goal of this study was to develop can-
didate vaccines against henipaviruses utilizing two well-established rhabdoviral vaccine vector platforms, recombinant rabies
virus (RABV) and recombinant vesicular stomatitis virus (VSV), expressing either the codon-optimized or the wild-type (wt)
HeV glycoprotein (G) gene. The RABV vector expressing the codon-optimized HeV G showed a 2- to 3-fold increase in incorpo-
ration compared to the RABV vector expressing wt HeV G. There was no significant difference in HeV G incorporation in the
VSV vectors expressing either wt or codon-optimized HeV G. Mice inoculated intranasally with any of these live recombinant
viruses showed no signs of disease, including weight loss, indicating that HeV G expression and incorporation did not increase
the neurotropism of the vaccine vectors. To test the immunogenicity of the vaccine candidates, we immunized mice intramuscu-
larly with either one dose of the live vaccines or 3 doses of 10g chemically inactivated viral particles. Increased codon-opti-
mized HeV G incorporation into RABV virions resulted in higher antibody titers against HeV G compared to inactivated RABV
virions expressing wt HeV G. The live VSV vectors inducedmore HeV G-specific antibodies as well as higher levels of HeV neu-
tralizing antibodies than the RABV vectors. In the case of killed particles, HeV neutralizing serum titers were very similar be-
tween the two platforms. These results indicated that killed RABVwith codon-optimized HeV G should be the vector of choice as
a dual vaccine in areas where rabies is endemic.
IMPORTANCE
Scientists have been tracking two new viruses carried by the Pteropid fruit bats: Hendra virus (HeV) and Nipah virus (NiV). Both
viruses can be fatal to humans and also pose a serious risk to domestic animals. A recent escalation in the frequency of outbreaks
has increased the need for a vaccine that prevents HeV and NiV infections. In this study, we performed an extensive comparison
of live and killed particles of two recombinant rhabdoviral vectors, rabies virus and vesicular stomatitis virus (VSV), expressing
wild-type or codon-optimized HeV glycoprotein, with the goal of developing a candidate vaccine against HeV. Based on our data
from the presented mouse immunogenicity studies, we conclude that a killed RABV vaccine would be highly effective against
HeV infections and would make an excellent vaccine candidate in areas where both RABV and henipaviruses pose a threat to
human health.
Hendra virus (HeV) and Nipah virus (NiV) are emerging zoo-notic viruses that belong to theHenipavirus genus within the
Paramyxoviridae family. Both are highly pathogenic in humans.
Henipaviruses are naturally harbored by Pteropid fruit bats
(commonly referred to as flying foxes) that undergo asymptom-
atic infections (1).Henipavirus-associated diseasewas initially de-
tected in horses and pigs, which likely were in contact with infec-
tive bat urine or droppings or contaminated fruit (2). However,
both viruses can infect a wide range of animal species (wild or
domestic), including humans. HeV and NiV have host-specific
respiratory or neurological tropism, and infections are associated
with high morbidity and case fatality rates of up to 75% (1, 3).
Henipaviruses are classified as biosafety level 4 (BSL4) pathogens
and considered to be bioterrorism and agroterrorism threats,
which increases the need for development and production of safe
and effective vaccines for livestock and humans (2, 4).
HeV emerged in 1994 in two separate outbreaks of severe re-
spiratory disease in horses with subsequent transmission to hu-
mans, who were in close contact with the infected horses (5).
Although initially called “equine morbillivirus,” because both of
the initial outbreaks involved horses, it was renamed “HeV” after
the first outbreak in the Brisbane suburb of Hendra, Queensland,
Australia. Investigations revealed that Pteropus species bats are the
primary reservoir of HeV (6).
NiV emerged in 1998 in a major outbreak of acute febrile en-
cephalitis in humans inMalaysia that resulted in 265 human cases
and 105 fatalities. The virus was named after the first isolated case
in a patient from the Sungai Nipah village. Investigations revealed
that the outbreak originated from infected pigs, in which the virus
caused a mild disease, but was then transmitted to humans
through close contact with the pigs (7, 8). In humans, both HeV
and NiV infections cause respiratory disease and/or severe neuro-
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logical disease that may eventually progress to coma and finally
death (1). HeV infection in horses predominantly causes death
due to severe respiratory disease, and the horses may show some
neurological symptoms (5).
Virus attachment, membrane fusion, and particle entry for
HeV and NiV requires two distinct, membrane-anchored glyco-
proteins: (i) a fusion (F) glycoprotein (type I membrane protein)
mediating the fusion of the viral and host cell membranes and (ii)
an attachment (G) glycoprotein (type II membrane protein) re-
quired for receptor binding and virion attachment to the host cell.
HeV G and HeV F share a high degree (83% to 89%) of similarity
to NiV G and NiV F (9).
The ability of henipaviruses to infect a wide range of mamma-
lian species appears to be linked to their cellular receptors, ephrins
B2 and B3 (10). Ephrin receptors are highly conserved across spe-
cies and to be involved in mediating short-range cell-to-cell com-
munication (11). Ephrin B2 is expressed in endothelial cells,
smooth muscle cells, bronchial epithelial cells, and cardiomyo-
cytes, whereas ephrin B3 ismostly restricted to the central nervous
system (12, 13). Notably, ephrins B2 and B3 have been identified
as functional receptors for HeV and NiV via their G glycoproteins
(9, 10), but NiV appears to have a higher affinity for ephrin B3
than HeV, which could explain the stronger neurotropism of NiV
(14).
Currently, researchers are exploring three different approaches
for the prevention and/or treatment of henipavirus infections.
The first approach utilizes human monoclonal antibodies (MAb)
that were selected from a human Fab phage display library for
their high binding to solubleHeV glycoprotein (sG). In particular,
the m102 antibody possessed potent virus-neutralizing activity
(15), which was further improved by in vitro maturation. This
improved MAb (m102.4) has been shown to protect ferrets from
lethal NiV challenge and African green monkeys (AGM) from
lethal HeV and lethal NiV challenge (16–19).
The second approach utilizes viral vaccines. Protection against
Nipah virus challenge was reported for recombinant vesicular sto-
matitis virus (VSV) and adeno-associated virus 8 (AAV8) viral
vaccines in the Syrian Hamster and ferret models (20–22). The
AAV8-NiV G vaccine also conferred partial cross-protection
against HeV challenge (23).
The third approach utilizes a recombinant subunit vaccine
sGHeV (containing an engineered secreted version of the full ect-
odomain of HeVG) that protects against bothHeV andNiV chal-
lenge in the AGM model, which recapitulates the severe clinical
symptoms and pathology associated with henipavirus infection in
humans (24, 25) Furthermore, the subunit vaccine Equivac HeV
demonstrated complete protection in horses and is now used by
the equine industry in Australia (26).
In our study, we aimed to develop a rhabdovirus-based vaccine
against HeV for humans and animals. Both, rabies virus (RABV)
and vesicular stomatitis virus (VSV) are members of the Rhabdo-
viridae family and are relatively simple, enveloped, negative-
stranded RNA viruses that encode five proteins (N, P, M, G, and
L). Vaccines based on both viruses have been shown to induce
potent humoral responses against other viral pathogens, but the
vectors have never been compared in parallel for the same patho-
gen. Our recombinant RABV vaccine vector is derived from the
live-attenuated RABV strain SAD B19 RABV, which is licensed
and used for wildlife vaccination in Europe and is nonpathogenic
in a wide range of animal species when administered orally or
intramuscularly (27–30). This strain was further attenuated by
switching an amino acid in the RABV glycoprotein (G), which
greatly reduces the neurotropism of the RABV strain (28, 31). The
recombinant VSV platform utilized here is an attenuated VSV
Indiana strain thatwas previously shown to be safe in small animal
models (32, 33). Both recombinant RABV- and VSV-based vac-
cine vectors have been shown to be safe and immunogenic in
nonhuman primates (33, 34).
MATERIALS AND METHODS
Antibodies.The humanmonoclonal antibody 4C12 against RABV glyco-
protein was provided by Scott Dessain (Lankenau Institute for Medical
Research, Wynnewood, PA), the mouse monoclonal antibody 41C3
against HeV glycoprotein was a generous gift from Christopher Broder
(Uniformed Services University, Bethesda, MD), and the hybridomas
producing monoclonal antibodies I1 and I14 against VSV glycoprotein
were provided by John Rose (Yale University, New Haven, CT).
cDNAconstructionof vaccine vectors.Weinserted codon-optimized
Hendra virus glycoprotein gene G (for vaccine “coHeVG” constructs
[gene synthesized by Genscript USA, Inc.]) or wild-type (wt) Hendra
glycoprotein gene G (for vaccine “HeVG” constructs) into the BsiWI and
NheI restriction sites of the BNSP333 RABV vector (30). The resulting
plasmids were designated RABV-coHeVG and RABV-HeVG, respec-
tively. The VSV-based vaccines were made by PCR amplification of the
coding region of HeVG with primers RP1163 (ATTACTCGAGGCCACC
ATGATGGCTGATTCCAAATTGGTAG) and RP1088 (GAGAGCTAGC
TTATCAACTCTCTGAACATTGGGCAGGT) or the coding region of
coHeVG with primers RP1170 (ACTGTACTCGAGGCCGCCACCATG
ATGGCCGACTCTAAACTGGTC) and RP1171 (ACTGTAGCTAGCT
CAGGACTCGCTGCACTGAGCTGGGAT). The resulting PCR products
were inserted into the XhoI and NheI restriction sites (between the G and
L genes) of the VSV vector cVSV-XN (35). The resulting plasmids were
designated VSV-HeVG and VSV-coHeVG, respectively. The correct se-
quences of all four plasmids were confirmed by sequencing.
Recoveryof recombinant vectors.RecombinantRABVandVSVwere
recovered as described previously (36, 37). Briefly, X-tremeGENE 9 trans-
fection reagent (RocheDiagnostics) inOpti-MEMwas used to cotransfect
the respective full-length viral cDNA clones along with the plasmids en-
coding RABVN, P, G, and L or VSVN, P, and L proteins and the T7 RNA
polymerase into BSR cells in 6-well plates (RABV) or 293T cells in T25
flasks (VSV). We harvested the supernatants of transfected cells after 7
days for transfection with RABV and after 3 days for VSV recoveries. We
then analyzed for the presence of infectious virus by immunostaining for
RABV or for virus-induced cytopathic effect (CPE) in the case of VSV.
Sucrose purification and inactivation of the virus particles. Larger
amounts of RABV-HeVG or RABV-coHeVG were concentrated in a
stirred 300-ml ultrafiltration cell (Millipore) and then spun through a
20% sucrose cushion in an SW32 Ti rotor (Beckman, Inc.) at 25,000 rpm
for 1.5 h. Recombinant VSVs were purified similarly but without prior
concentration in ultrafiltration cells. Virion pellets were resuspended in
phosphate-buffered saline (PBS), and protein concentrations were deter-
mined using a bicinchoninic acid (BCA) assay kit (Pierce). The virus
particles were inactivated with 50l permg of particles of a 1:100 dilution
of -propiolactone (BPL) in cold water. The absence of infectious parti-
cles was verified by inoculating BSR cells with 10 g of BPL-inactivated
viruses. After 4 days of incubation at 34°C, the cells were subcultured and
500 l of supernatant was passaged on fresh BSR cells. Cultures were
examined 4 days later for absence of cytopathogenicity forVSV and lack of
staining with a fluorescein isothiocyanate (FITC)-conjugated anti-RABV
NMAb for RABV.
Virus characterization. The virus particles were denatured with urea
buffer (125mMTris-HCl [pH 6.8], 8M urea, 4% sodium dodecyl sulfate,
5% -mercaptoethanol, 0.02% bromophenol blue) at 95°C for 5 min.
Threemicrograms of protein was resolved on a 10% SDS–polyacrylamide
gel and thereafter stained overnight with SYPRO Ruby for total protein
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analysis or transferred onto a nitrocellulose membrane in Towbin buffer
(192 mM glycine, 25 mm Tris, 20% methanol) for Western blot analysis.
The nitrocellulose membrane was then blocked in TBST (100 mM Tris-
HCl [pH 7.9], 150mMNaCl, 0.05%Tween 20) containing 5% driedmilk
at room temperature for 1 h. After blocking, themembranewas incubated
overnight with antisera obtained from a convalescent HeV-infected Afri-
can green monkey at a dilution of 1:1,000 in 5% bovine serum albumin
(BSA). After washing, the blot was incubated for 1 h with horseradish
peroxidase (HRP)-conjugated anti-human IgG diluted 1:50,000 in block-
ing buffer. Bands were developed with SuperSignal West Dura Chemilu-
minescent substrate (Pierce). The incorporation of HeV Gwas compared
between the different cell lines, wt and coHevG-expressing viruses, and
also between the two rhabdovirus vectors utilizing AlphaView software
(ProteinSimple) for quantification of SYPRO Ruby-stained SDS-PAGE
gels. To account for differences in particle load, the amount of HeVGwas
normalized to the amount of RABV or VSVN, which is equal for particles
with the same genome length.
FACS analysis. A total of 8  105 Vero cells were seeded in 6-well
plates. For the VSV fluorescence-activated cell sorter (FACS) analysis,
cells were infected with VSV-HeVG, VSV-coHeVG, or VSV expressing
Zaire Ebola virus (ZEBOV) glycoprotein (VSV-ZGP) at a multiplicity of
infection (MOI) of 5 or left uninfected (control) for 6.5 h. For the RABV
FACS analysis, cells were infected with RABV-HeVG, RABV-coHeVG, or
RABV at an MOI of 10 or were left uninfected (control) for 48 h. After
infection, the medium was aspirated and cells were washed with 1 ml 1
PBS once. Three hundred microliters of 1 PBS-EDTA buffer was added
per well for 5 to 10 min to help dissociate the cells from the well. The cells
were transferred to 5-ml round-bottom tubes and washed twice in 1ml of
1 PBS by centrifugation at 400 g for 3 min. Cells were resuspended in
1 ml of 2% paraformaldehyde and fixed for 30 min at room temperature,
followed by permeabilization in 500l Perm buffer (0.25%Tween 20 and
2% paraformaldehyde in 1 PBS). The cells were washed three times in
FACS buffer (5% fetal bovine serum [FBS] and 0.02% NaN3 in 1 PBS).
Staining was performed in a 96-well round-bottom plate. The VSV-in-
fected cells were stained in 50l of VSVGmousemonoclonal antibody I1
(38) or 50l of HeVGmousemonoclonal antibody 41C3 in FACS buffer
for 30 min at room temperature. The RABV-infected cells were stained in
50 l of the primary antibody mixture containing the RABV G human
monoclonal antibody 4C12 and the HeV G mouse monoclonal antibody
41C3 in FACS buffer for 30 min at room temperature. This was followed
by washing the cells twice in 200 l FACS buffer. The VSV-infected cells
were stained in 50 l of donkey anti-mouse IgG conjugated to Cy3 in
FACS buffer for 30min at room temperature, whereas the RABV-infected
cells were stained in 50 l of a secondary antibody mixture of donkey
anti-human IgG DyLight 649 and donkey anti-mouse IgG conjugated to
Cy3 in FACS buffer for 30 min at room temperature, followed by being
washed twice with 200 l FACS buffer. VSV-infected cells were analyzed
for Cy3 emission to detect VSV G or HeV G in the PE-Texas Red channel
using a BD LSRII. The RABV-infected cells were analyzed for Cy3 emis-
sion to detect HeV G in the phycoerythrin (PE)-Texas Red channel and
DyLight 649 emission to detect RABV G in the allophycocyanin (APC)
channel using a BD LSRII. Data analysis was performed using FloJo soft-
ware (Treestar, Ashland, OR).
Pathogenicity and immunogenicity studies. (i) Animal ethics state-
ment. This study was carried out in strict adherence to recommendations
described in the Guide for the Care and Use of Laboratory Animals (39), as
well as guidelines of theNational Institutes ofHealth, theOffice of Animal
Welfare, and the United States Department of Agriculture. All animal
work was approved by the Institutional Animal Care and Use Committee
(IACUC) at Thomas Jefferson University (animal protocols 414I and
414N). All procedures were carried out under isoflurane anesthesia by
trained personnel, under the supervision of veterinary staff. Mice were
housed in cages, in groups of five, under controlled conditions of humid-
ity, temperature, and light (12-h light/12-h dark cycles). Food and water
were available ad libitum.
(ii) Pathogenicity experiments. Five groups of five 6- to 8-week-old
Swiss Webster mice were intranasally (i.n.) infected with 105 PFU (VSV)
or focus-forming units (FFU) (RABV) of the live viruses diluted in 20 l
phosphate-buffered saline (PBS). The mice were weighed daily and mon-
itored for signs of disease until day 28 postinfection. Mice that lost more
than 20% weight were euthanized.
(iii) Immunizations.Ten groups of five 6- to 8-week-oldBALB/cmice
were immunized intramuscularly (i.m.) with 106 PFUor FFUof live virus,
or 10 g BPL-inactivated virus (3 doses at 0, 14, and 28 days) (see Fig. 4).
All i.m. immunizations were performed by administering 50 l of live or
BPL-inactivated virus into each hind leg muscle. For serum collection,
retro-orbital bleeds were performed under isoflurane anasthesia on days
0, 7, 14, 21, 28, and 35, with the final bleed on day 87. Sera from individual
mice as well as pooled sera were analyzed for HeVG, RABVG, and VSVG
IgG responses.
(iv) Production of HA-tagged HeV G. Subconfluent T175 flasks of
293T cells (human kidney cell line) were transfected with a pDisplay vec-
tor encoding amino acids 71 to 604 of the globular head and the stalk
domains of the HeV G fused to an N-terminal hemagglutinin (HA) pep-
tide. Supernatant was collected between days 5 to 7 posttransfection and
loaded onto an equilibrated anti-HA agarose (Pierce) column containing
a 2.5-ml agarose bed volume. The column was washed with 10 bed vol-
umes of TBST (TBS containing 0.05% Tween 20) and 2 bed volumes of
TBS. After 2 h of incubation at room temperature, antibody-bound HeV
G was eluted with 5 ml of 250 g/ml HA peptide in TBS. Fractions were
collected and analyzed for HeV G by Western blotting with monoclonal
anti-HA antibody (Sigma) prepared in 5% BSA–TBST. Peak fractions
were then pooled and dialyzed against PBS in 10,000 molecular weight
cutoff (MWCO) dialysis cassettes (Thermo Scientific) to remove excess
HApeptide. After dialysis, the proteinwas quantitated byUV spectropho-
tometry and frozen in small aliquots at80°C.
(v) Analysis of immune response to immunization. We tested indi-
vidual mouse sera as well as pooled sera by enzyme-linked immunosor-
bent assay (ELISA) for the presence of IgG specific to HeV G, RABV G,
and VSV G. In order to test for anti-HeV G humoral responses, we pro-
duced soluble HeV G (sHeV G) as described above. sHeV G was resus-
pended in coating buffer (50mMNa2CO3 [pH 9.6]) at a concentration of
500 ng/ml and then plated in 96-well ELISA MaxiSorp plates (Nunc) at
100 l in each well. RABV G and VSV G were similarly resuspended in
coating buffer (50 mM Na2CO3 [pH 9.6]) at a concentration of 1 g/ml
and then plated in 96-well ELISA MaxiSorp plates (Nunc) at 100 l per
well. After overnight incubation at 4°C, plates were washed three times
with PBST (0.05% Tween 20 in 1 PBS), which was followed by the
addition of 250l blocking buffer (5% drymilk powder in 1 PBST) and
incubation at room temperature for 1 h. The plates were then washed
three timeswith PBST and incubated overnight at 4°Cwith serial dilutions
of sera in PBS containing 0.5% BSA. Plates were washed three times the
next day, followed by the addition of horseradish peroxidase-conjugated
goat anti-mouse-IgG (HL) secondary antibody (1:20,000) (Jackson Im-
munoResearch). After incubation for 2 h at room temperature, plates
were washed three times with PBST, and 200 l of o-phenylenediamine
dihydrochloride (OPD) substrate (Sigma) was added to each well. The
reaction was stopped by the addition of 50 l of 3 M H2SO4 per well.
Optical density was determined at 490 nm (OD490). IgG subclass-specific
enzyme-linked immunosorbent assays (ELISAs) were performed for HeV
G utilizing pooled sera (day 35) as described above for analysis of total
anti-HeVG IgG. Three-fold serial dilutions of sera were prepared starting
at a 1:150 dilution. Secondary antibodies specific for mouse IgG1 and
IgG2a were diluted 1:2,000 or 1:20,000, respectively, in PBST, and 100 l
was added per well. Plates were incubated for 10 min with OPD substrate
before the reaction was stopped with 3 M H2SO4. ELISA data were ana-
lyzed with GraphPad Prism using a sigmoidal nonlinear fit model to de-
termine the titer at which the curves reach 50% of the top plateau value
(50% effective concentration [EC50]).
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Virus neutralization assays against HeV and NiV. We prepared a
2-fold dilution series of the mouse serum samples starting at 1:10 in Dul-
becco’smodified Eagle’smedium (DMEM)–2%FBS.HeV andNiV (Ban-
gladesh isolate) were diluted in DMEM–2% FBS, achieving a final titer of
2,000 TCID50/ml. Fifty microliters of virus (100 50% tissue culture infec-
tive doses [TCID50]) was then incubated with 50 l serum (day 85, heat
inactivated) dilution for 60 min at 37°C. The virus-serum mixture was
then added to a 96-well plate confluent with Vero cells and incubated for
3 days (NiV) or 5 days (HeV) at 37°C. Cytopathic effect (CPE) was re-
corded, and the lowest serum dilution at which no CPE on the Vero cells
was detected was recorded as the virus neutralizing titer.
RESULTS
Rescue of recombinant viruses. The so-called “BNSP” RABV
vaccine vector is derived from the RABV SAD B19 vaccine strain,
which was attenuated by tissue culture passage (27, 30). The con-
struct was engineered to contain an additional RABV stop-start
transcription signal sequence flanked by unique BsiWI and NheI
restriction sites between the nucleoprotein (N) and phosphopro-
tein (P) genes for introduction of foreign genes (Fig. 1). While
BNSP is avirulent after peripheral administration in mice, it re-
tains neurovirulence after intracerebral inoculation (40). There-
FIG 1 RABV- and VSV-based vaccine vectors. Shown is a schematic repre-
sentation of the parental vectors (RABV and VSV) and the vaccine constructs
expressing wild-type HeV G [RABV-HeVG (wt) and VSV-HeVG (wt)] or
codon-optimized HeV G (RABV-coHeVG and VSV-coHeVG).
FIG 2 FACS analysis of expression of viral glycoproteins. Vero cells were infected with the recombinant RABVs or VSVs as indicated. Forty-eight hours (RABV)
or 6.5 h (VSV) after infection, cells were stained with antibodies directed against RABV G, VSV G, or HeV G, as indicated, and analyzed by FACS. The numbers
indicate the mean fluorescence intensity (MFI) for each staining.
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fore, a further-attenuated derivative, BNSP333, was generated
that contained an Arg¡Glu change at amino acid 333 of the
RABV G (31, 41). Studies in adult mice showed that this 333 mu-
tation greatly reduced the neurovirulence observed with previous
RABV vaccine vectors (28, 34, 40, 42).
The recombinant VSV (rVSV) vector VSV-XN, initially devel-
oped by Schnell et al. (35), is based on an infectious cDNA clone of
the VSV Indiana serotype (32). It was modified by introducing a
stop-start transcription signal sequence flanked by unique XhoI
and NheI restriction sites between the glycoprotein (G) and large
polymerase protein (L) genes for introduction of foreign genes
(35). rVSV has been used to develop immunization strategies
against a large number of pathogens, including influenza virus
(43), Ebola virus (EBOV) (44), and human immunodeficiency
virus (HIV) (45).
The goal of this study was to compare immunogenicity and
safety in a small animal model of the two rhabdoviral vector plat-
forms expressing the same foreign antigen. In order to generate
the rRABV and rVSV vaccines expressing either wt or codon-
optimized HeV G (coHeV G), we amplified the respective HeV G
open reading frames (ORF) and inserted them into the RABV
vector downstream of the RABV N gene between the BsiWI and
NheI sites.We generated the rVSVvectors similarly, by amplifying
the two respective HeV G ORFs and then inserting them into the
plasmid downstream of the VSV G gene using the XhoI and the
NheI sites. We recovered recombinant vaccine vectors RABV-
HeVG, RABV-coHeVG, VSV-HeVG, and VSV-coHeVG by stan-
dard methods as described in Materials and Methods (46–49).
Characterization of recombinant viruses.Next, we wanted to
determine the expression levels ofHeVGand analyze the effects of
codon optimization on HeV G expression and incorporation into
virions for the four different vectors. For this approach, we in-
fected different cell lines with RABV-HeVG, RABV-coHeVG, or
the RABV control for 48 h or VSV-HeVG, VSV-coHeV, or the
VSV-ZGP control for 6.5 h. Cells were then harvested, fixed, and
stainedwith an antibody directed againstHeVG,RABVG, orVSV
G and analyzed by FACS. The results (Vero cells) are shown in Fig.
2. For the RABV-based constructs (RABV-HeVG and RABV-co-
HeVG), the detected expression level for coHeV G was about 2.5-
fold higher than that for wt HeV G (Fig. 2A). In contrast, no
significant difference was detected in HeV G expression for the
two VSV constructs (VSV-HeVG and VSV-coHeVG) (Fig. 2B).
In the next step, we analyzed purified virions from BSR, 293T,
or Vero cells infected with the four viruses by 10% SDS-PAGE.
When we evaluated the SYPRO Ruby-stained gels, we found that
HeVG incorporationwas highest in Vero cell-derived virions, less
in the BSR cell-derived virions, and lowest in 293T cell-derived
virions for both RABV and VSV for both wt and coHeV G (data
not shown). As shown in Fig. 3A (Vero cell-derived virions), a
prominent monomeric protein band of80 kDa was detected in
all the vaccine vectors expressingHeVG. Interestingly, we initially
observed a less prominent band migrating above the 220-kDa
marker for the four recombinant viruses expressing HeV G. This
was similar to the results previously shown by Bossart et al. (15),
wherein they showed a tetrameric band of partially reduced HeV
G. This band disappeared after prolonged heating in reducing
sample buffer (Fig. 3A). Western blot analysis of sucrose-purified
virus particles confirmed that the additional 80-kDa band is
HeV G (Fig. 3B). The quantification results of the SYPRO Ruby-
stained gels showed that HeVG incorporationwas 2.5 to 3.5 times
higher in RABV-coHeVG virions than RABV-HeVG virions. No-
tably we observed a slight increase in incorporation level at later
harvests of the RABV-coHeVG virus with a concomitant slight
reduction in RABV G levels (data not shown). We only obtained
small differences for HeV G incorporation comparing VSV-co-
HeVG toVSV-HeVG (e.g.,10%more [data not shown]), a find-
ing that was consistentwith the similar expression levels of the two
proteins as detected by FACS. When we compared VSV-coHeVG
and RABV-coHeVG, we observed a 70% increased incorporation
of HeV G into VSV particles.
Incorporation of HeV G into RABV or VSV does not change
vector pathogenicity.BothRABV andVSV vectors utilized in this
study are highly attenuated. However, HeV G is known to bind to
receptors that are present on neuronal cells, which could poten-
tially restore the neurotropism of the RABV and/or VSV vectors
and make them more pathogenic than the parental strains. To
study the pathogenicity of the vaccine vectors, five groups of five
Swiss Webster mice were infected intranasally (i.n.) with 1 105
plaque-forming units (PFU) of the live viruses and monitored for
28 days. The introduction and expression of HeV G into both
vectors (VSV-coHeVG and RABV-coHeVG) did not result in any
increase in pathogenicity, as indicated by the lack of clinical symp-
toms or weight loss in the infectedmice (Fig. 4). There was also no
pathogenicity observed with the control vector expressing Ebola
(Zaire) virus glycoprotein (ZEBOV-GP) (BNSP333-ZGP in Fig.
4) (40), whereas all mice infected with the neurotropic control
FIG 3 Analysis of purified virions of vaccine vectors. Purified virions (Vero
cell derived) from RABV-coHeVG, RABV-HeVG, RABV, VSV-coHeVG,
VSV-HeVG, or VSV-GFP were separated by SDS-PAGE and stained with SY-
PRO Ruby for total protein analysis (A) or transferred to a nitrocellulose
membrane, and HeV Gwas detected byWestern blotting (B). LaneM, molec-
ular mass markers.
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RABV vector BNSP succumbed to infection; this was previously
shown byMcGettigan et al. (28). Furthermore, we observed resid-
ual pathogenicity (weight loss) for infection with the control vec-
tor expressing green fluorescent protein, VSV-GFP (Fig. 4).
Immune responses to the vaccines. The goal of this study was
tomeasure antibody responses against HeVG of the two different
vaccine vectors based on RABV or VSV, to compare live and in-
activated vaccines (3 doses), and to determine whether the vectors
can be further improved by utilizing codon optimization of the
viral antigen. We assessed the humoral immune response to vac-
cination in a BALB/c mouse model immunized intramuscularly
with live or inactivated RABV or VSV (Fig. 5) over a period of 35
days.
Immunogenicity against HeV G. To analyze the HeV G-spe-
cific humoral responses, we purified the HA-tagged ectodomain
of HeV G (sHeV G) from the supernatant of transiently trans-
fected 293T cells by affinity column purification. We used the
purified sHeVG to coat ELISA plates, as outlined inMaterials and
Methods, and analyzed sera from the immunized mice for the
presence of HeV G-specific antibodies. The results in Fig. 6 indi-
cate that seroconversion against HeV G occurred as early as day 7
after vaccination with the BPL-inactivated RABV [RABV-HeVG
(BPL), RABV-coHeVG (BPL)] and all VSV-based vectors (live
and BPL inactivated). In contrast, the anti-HeV G humoral re-
sponses induced by the live RABV vectors were close to the back-
ground level for both the wt HeV G and for the RABV-coHeVG
vaccines. We observed no HeV G-specific responses for the con-
trols (live and killedRABVvaccinewithout theHeVG insert) (Fig.
6) (data not shown).
HeV G-specific humoral responses were detectable on day 14
at similar levels for all VSV-based vaccines (live and BPL inacti-
vated) and lower, but significant immune responses for the
RABV-based vaccines. Interestingly, codon-optimized HeV G in-
creased HeV G-specific immunity for both live and inactivated
RABV vaccines (Fig. 6).
There was a large increase in the HeV G-specific IgG titers on
day 21, 7 days after the first boost on day 14 with the inactivated
viruses. The highest increase was measured for the VSV-coHevG
BPL-inactivated vaccine, followed by the RABV-coHeVG BPL-
inactivated vaccine. The RABV-HeVG BPL-inactivated vaccine
induced a higher HeV G-specific IgG titer on day 21 compared to
day 14, yet a lower IgG response in comparison to the coHeV
G-expressing vaccines. The IgG titers for HeVG increased slightly
from day 21 to day 35 for all of the BPL-inactivated vaccines after
the second boost on day 28.On days 28 and 35, theHeVG-specific
IgG titers were the highest for the BPL-inactivated VSV-coHeVG
FIG 4 Pathogenicity study in Swiss Webster mice. Shown are weight curves of infected mice (Ms 1 to Ms 5) after i.n. inoculation with 105 PFU VSV or 105 FFU
RABV live virus as indicated.
FIG 5 Experimental timeline of immunization study. BALB/c mice were im-
munized with either one dose of 105 PFU of live virus (day 0) or 3 doses of 10
g inactivated virus (days 0, 14, and 28). Serumwas collected every 7 days until
day 35 and analyzed by ELISA. Final serum samples were collected on day 85
and used for determination of antibody neutralization titers.
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FIG 6 Analysis of anti-HeVG humoral immune response of immunizedmice. BALB/c mice were immunized as indicated in the legend to Fig. 5, and blood was
collected on days 0, 7, 14, 21, 28, and 35. Serum was pooled from each group and analyzed for total IgG against HeV G by ELISA. All sera were diluted 1:50 and
analyzed in 3-fold dilutions; the error bars indicate the standard deviations of the samples analyzed in triplicates. The nonlinear curve fit of the group with the
highest titer (BPL-inactivated VSV-coHeVG at day 35 postimmunization) is shown as a red dotted curve in all graphs for comparative reference. OD490, optical
density at 490 nm.
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vaccine, followed by the BPL-inactivated RABV-coHeVG and
RABV-HeVG vaccines.
In summary, the administration of three doses of BPL-inacti-
vated vaccines induced a higher anti-HeVG-specific IgG response
than a single dose of live vaccines for the RABV- and VSV-based
vectors. Among the live vaccines, the total IgG response against
HeV G was highest for the VSV live vaccine (endpoint titer,
1:984,150) and about 10-fold less for the vaccines RABV-coHeVG
and RABV-HeVG (endpoint titer, 1:109,000) (Table 1). Among
the killed particle-based vaccines, endpoint titers were more sim-
ilar for VSV and RABV (Table 1). Notably, the final titer for both
the live and the killed RABV-based vaccine vectors was unaffected
by the codon optimization of HeV G. However, the HeV G-spe-
cific total IgG response developed faster for all RABV-coHeVG-
based vaccines. Also, we noted qualitative antibody differences
between the wt HeVG and coHeVG vectors, as indicated below.
HeVandNiVneutralization assays.To analyze the potency of
the final sera (day 85) of the immunized mice, we performed a
virus neutralization assay (VNA) against HeV andNiV. Sera from
all mice immunized with killed or live HeV G vaccines induced
VNA against Hendra virus (Table 1). The ELISA titers correlated
to some extent with the neutralization titers, with less-pro-
nounced differences in the HeV G-specific ELISA. For example,
the VNA titers for the killed particles were very similar for RABV
and VSV, whereas the ELISA titers were 3-fold different. As a
general trend, high neutralization titers againstHeV also provided
some cross-neutralization against NiV, whereas the lower titers
did not provide any neutralizing activity against the heterologous
virus.
Antibody quality.Antibody quality can play an important role
in protecting the infected host. Therefore, we further analyzed the
composition of the total anti-HeVG IgG for IgG1 versus IgG2a
classes. As shown in Fig. 7, the IgG responses were mostly Th1
biased (IgG2a). The lack of detectable IgG1 was most notable for
the two live RABV vectors. It was less pronounced for the live VSV
vectors, even though we also observed a Th1 bias with a IgG2a/
IgG1 ratio of 2. Interestingly, it appears that the higher incorpo-
ration rate of coHeV G into RABV virions also skewed the im-
mune response toward Th1 as seen for the sera from mice
immunized with killed particles of RABV-HeVG compared to
RABV-coHeVG. Further experiments are needed to analyze
whether the differences in isotype bias for the different vaccines
also affect differences in protection, as proposed for other viruses,
such as EBOV.
RABV and VSVG response. In order to determine the vector-
specific immune response, we also analyzed the humoral re-
sponses to RABV G and VSV G, respectively (Fig. 8A and B). We
observed that the administration of three doses of BPL-inactivated
virus particles induced a higher vector-specific response than one
dose of live virus. The difference was quite significant for the
RABV vaccines but much smaller for the VSV vaccines. Among
the live RABV vaccines, no significant difference was observed
between the parental RABV vector and the RABV vaccines ex-
pressing wt or coHeV G. However, among the BPL-inactivated
RABV vectors, a slight decrease in vector-specific immune re-
sponse was seen for the RABV-coHeVG vaccine compared to the
parental vector. This result indicated that the incorporation of a
foreign protein into the virion membrane can interfere with
RABV G-specific immunity.
DISCUSSION
The high mortality rate of both HeV and NiV infections in hu-
mans, in combination with the frequent spillovers observed in
recent years, has raised interest in a vaccine against henipaviruses
for human use. In the past decade, researchers have developed
multiple vaccine and monoclonal antibody approaches against
henipaviruses and tested them in animal models (15, 16, 18, 24,
25, 50). However, only one of the candidate vaccines, an HeV
subunit vaccine for immunization of horses, has been licensed to
date (50). In this study, we evaluated and compared the immuno-
genicities of two well-established rhabdoviral platforms express-
ing HeV G in a mouse model. The decision to use VSV and RABV
vectors was based on their excellent safety record and their ability
to induce neutralizing antibody responses against other viral
pathogens (28, 34, 40, 45, 46, 48, 51, 52).We performed this study
with the ultimate goal of developing a vaccine for use in humans
and animals. We also wanted to compare VSV and RABV vectors
in parallel, which has not been done before.
FIG 7 Anti-HeVG IgG isotype analysis of immunized mice. Serum from
BALB/cmice collected 35 days after immunization (see Fig. 5)was analyzed for
the presence of anti-HeVG IgG1 and IgG2a by ELISA. The graph shows the
IgG2a/IgG1 EC50 ratio of the sera.
TABLE 1 Virus neutralization assay and endpoint titer results from sera






RABV-HeVG 109,000 1:120 NNa
RABV-coHeVG 109,000 1:60 NN
RABV-HeVG inactivated 984,150 1:480 NN
RABV-coHeVG inactivated 984,150 1:1,280 1:40
VSV-HeVG 984,150 1:640 1:10
VSV-coHeVG 984,150 1:960 1:160
VSV-coHeVG inactivated 2,952,450 1:1,920 1:80
RABV 1,350 NN NN
RABV inactivated 1,350 NN NN
PBS 1,350 NN NN
a NN, nonneutralizing antibodies.
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In agreement with previous studies, we observed efficient in-
corporation of HeV G into RABV and VSV particles. Numerous
studies have shown that both RABV and VSV can incorporate
foreign glycoproteins into their envelope (for a review, see refer-
ences 33 and 41). Incorporation levels can vary widely fromnearly
undetectable levels in the case of cellular receptor proteins (53, 54)
to more than 10% of total glycoprotein in the case of other viral
envelope proteins (43, 49). The latter do not generally require the
presence of a rhabdovirus-specific incorporation signal (49). This
was demonstrated by the efficient pseudotyping of VSV with sev-
eral viral glycoproteins, including HeV G (55, 56). In other stud-
ies, RABV vectors efficiently incorporated ZEBOV GP (40) and
hepatitis C virus E2 (57) in the presence or absence of RABV G.
Also, ZEBOV GP incorporation was not dependent on or en-
hanced by the exchange of the GP transmembrane (TM) domain
with that of the RABV G TM domain (40), whereas efficient in-
corporation of CD4 and CXCR4 depended on the presence of the
RABV G cytoplasmic tail (54). This difference most likely occurs
because certain viral glycoproteins already harbor transport sig-
nals that direct them to common viral budding sites. In contrast,
the cellular receptors CD4 and CXCR4 lack these signals and are
targeted to different intracellular locations, as shown for VSV
(58). Taken together, these studies indicate that rhabdoviruses can
incorporate foreign glycoproteins indiscriminately, provided they
are present at sufficient levels at the budding site.
Based on this conclusion, we hypothesized that codon optimi-
zation would result in a higher protein expression and conse-
quently a higher level of HeV G incorporation into virions. This
proved to be true for the recombinant RABV vectors but not for
the recombinant VSVs. The reasons for this difference are unclear,
but the difference could be caused by the faster transport of VSVG
(59) compared to RABV G (60), the rapid replication cycle of
VSV, or the fast shutoff of host protein translation in VSV-in-
fected cells.
Even though the incorporation levels achieved with the vectors
described here are sufficient to induce strong humoral immune
responses against HeV G, it might be worth exploring other ways
to increase incorporation levels. For instance, pseudotyping of
lentiviral particles with HeV G can be made more efficient if the
cytoplasmic tail of G is truncated (55, 61). The same strategy
might also improve incorporation into VSV and RABV particles.
In addition to being immunogenic and efficacious against their
target pathogen, vaccine candidates need to be proven safe. Al-
though the RABV and VSV vectors used here were previously
shown to be safe, it is possible that the addition of HeV G could
have restored the neurotropism of the vectors and made them
more pathogenic than the parental vectors, since HeV itself is
neurotropic and able to bind to a highly conserved receptor on
neuronal cells (10). The results of the pathogenicity experiment
indicated that this is not the case and that the vaccines are still
attenuated, which confirmed the excellent safety profile of the
VSV and RABV vectors in numerous previous studies. However,
further studies would be needed to confirm that they are apatho-
genic and safe for humanuse (62).Of note, killed viral particles are
always considered safer because they cannot replicate.
The findings of this study indicate that live VSV vectors induce
higher immune responses against HeV G than live RABV vectors.
We have hypothesized that this is due to the faster viral replication
cycle of VSV, which causes very high viral loads early in infection
and therefore induces an anti-HeV G response before the vector
can be neutralized. Conversely, RABV is a slow-growing virus that
is likely neutralized before it can induce such high anti-HeV G
humoral responses. Since the immune responses against foreign
glycoproteins, such as ZEBOVGP, have been shown to be protec-
tive (34, 40), the next step needs to be a challenge experiment to
analyze the protective parameter of such antibodies against HeV.
We also showed that BPL-inactivated rhabdoviral particles in-
duced higher antibody titers than the live vaccineswith the highest
antibody titers detected for VSV-based particles. We speculate
that the reason for the higher induction of HeV G-specific im-
mune responses by BPL-inactivated VSV-coHeVG particles com-
pared to RABV-inactivated virions could be due to the different
receptor usage by VSV G versus RABV G. This difference could
influence the efficiency of uptake by dendritic cells, macrophages,
or other antigen-presenting cells. However, the VNA results were
only modestly different for the inactivated RABV and VSV vac-
cines expressing codon-optimized HeVG. Therefore, BPL-inacti-
vated RABV particles are the vaccine of choice based on the avail-
ability of a production line and the advantage of a dual vaccine
providing protection against RABV in addition to HeV. In addi-
tion, the inactivated particles can be administered multiple times
to boost their immunogenicity. This is not possible for the live
vaccines due to the antivector immunity induced after the first
FIG 8 Humoral vector response to RABV G or VSV G. Total IgG to RABV G (A) or VSV G (B) was determined from the sera collected at day 35 after
immunizationwith the different vaccines. All serawere diluted 1:50 and analyzed in 3-fold dilutions specific forRABVG(A) orVSVG(B). The error bars indicate
the standard deviations of the samples analyzed in triplicates.
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inoculation and certainly explains the lower antibody titers elic-
ited by the live viruses compared to the BPL-treated particles.
Th1-biased immune responses are generally considered bene-
ficial against viral infections. Previous studies by others have indi-
cated that BALB/c mice, which we also utilized in our study, have
a predisposition for mounting a Th2-biased immune response
(63). Hence, we conclude that the Th1-biased response we ob-
served in the immunized mice should most likely be similarly
induced in other species. Interestingly, the codon optimization of
HeV G increased the Th1-biased responses for both VSV and
RABV. This observation warrants further studies to determine
whether similar changes in antibody quality can be replicatedwith
rhabdoviral vectors expressing other viral glycoproteins.
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